Dhyana

Avatar

About Dhyana

This author has not yet filled in any details.
So far Dhyana has created 18 blog entries.

HIFU for prostate cancer shows excellent results in new study

Kia Michel, MD The 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Washington, D.C. featured Dr. Kia Michel, of Beverly Hills, Calif., who spoke on the outstanding data on focal HIFU outcomes for localized prostate cancer. Dr. Michel presented a poster on near-term HIFU outcomes based on his experience treating men with localized prostate cancer with the Sonablate. He presented that 78 men with prostate cancer underwent HIFU and were tracked post-treatment and re-biopsied at 12 months. He concluded that there was excellent disease control after HIFU ablation and most men were able to retain full urinary continence and erectile function levels equal to those pre-HIFU treatment. “I feel like it is important to report on [...]

2020-02-10T14:04:05-08:00February 10th, 2020|

Study reveals that being active has significant impact on prostate cancer risk

Prostate cancer is the number one cancer risk for men, as well as the No. 2 cancer killer behind lung cancer in the US, yet we still don't know all of its causes. The largest ever study to use genetics as a measurement for physical activity to look at its effect on prostate cancer, reveals that being more active reduces the risk of prostate cancer. Over 140,000 men were included in the study, of which, 80,000 had prostate cancer. This new study, published in the International Journal of Epidemiology in December, was led by the University of Bristol and co-funded by World Cancer Research Fund (WCRF) and Cancer Research UK (CRUK). It found that people with the variation in their DNA sequence that [...]

2020-02-04T13:01:18-08:00February 4th, 2020|

Benefits of HIFU technology revealed in 3 studies and reports

Three articles have appeared in press since June 2018 based on clinical trials undertaken in the U.K., that highlight the medium to long-term durability of Sonablate treatments in the control of prostate cancer when used in the partial gland ablation setting.1,2,3  Across the three articles and a total of more than 1,800 men, salvage free survival (no need for a whole gland or systemic treatment) was greater than 90% out as far as 60 months.  This excellent disease control was accompanied by a pad-free incontinence rate of greater than 98% and maintenance of erectile function in more than 80% of men. An additional article based on Canadian experience produced roughly similar results. 14 Dr. Mark Carol, CEO of SonaCare Medical writes,“While few will [...]

2020-01-27T13:26:59-08:00January 27th, 2020|

Obesity and a high-fat diet promote prostate cancer progression

Metabolites from a fatty diet join forces with the cancer-driving gene MYC to reprogram prostate cancer cells to grow faster, finds new study. This discovery solidifies a direct link between obesity and lethal prostate cancer. At the 2016 Annual American Association for Cancer Research (AACR) Conference, Giorgia Zadra, PhD, of the Harvard: Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented results from a study that helped to clarify the relationship between obesity and prostate cancer. The skinny? Fat increases the activity of a critical cancer-driving gene called MYC. Cancer is a greedy disease. Tumors plunder the body's resources - vitamins and nutrients, energy and oxygen, and vital space as tumors grow to ultimately cause lethal damage. Worst of all, cancer steals precious time away [...]

2017-12-13T13:37:22-08:00July 5th, 2016|

Mayo Clinic: Tips on Prostate cancer prevention

There's no proven prostate cancer prevention strategy. But one way to reduce the risk of prostate cancer is by making healthy choices, such as exercising and eating a healthy diet. Study results often conflict with each other and most studies aren't designed to definitively prove whether something prevents prostate cancer. As a result, no clear ways to prevent prostate cancer have emerged. In general, doctors recommend that men with an average risk of prostate cancer make choices that benefit their overall health if they're interested in prostate cancer prevention. Choose a healthy diet There is some evidence that choosing a healthy diet that's low in fat and full of fruits and vegetables may contribute to a lower risk of prostate cancer, though this hasn't been [...]

2017-12-13T13:37:22-08:00June 28th, 2016|

New Study: PSA levels in younger men might predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk. Smarter screening strategies that can improve the accuracy of diagnosing lethal prostate cancer are urgently needed. Through a prospective study of US men, investigators from Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health have found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future risk of lethal prostate cancer later in life. Their findings suggest that screening PSA levels in men [...]

2017-12-13T13:37:22-08:00June 21st, 2016|

California HIFU and Dr. Michael Lazar Recognizes Men’s Health Month With a Look at Prostate Cancer

California HIFU and Dr. Michael Lazar are helping to recognize Men’s Health Month by providing some valuable information and resources for men on Prostate Cancer. The idea behind Men's Health Month is to heighten the awareness of preventable health problems like prostate cancer, and to encourage early detection and treatment. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Informed Decision Making According to The Center for Disease Control and Prevention (CDC) it is important for men to be aware of prostate cancer risks and to make informed decisions. This happens best when a man— [...]

2017-12-13T13:37:22-08:00June 14th, 2016|

Focal Therapy For Prostate Cancer

 Focal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate. Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed. Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary [...]

2017-12-13T13:37:22-08:00May 3rd, 2016|

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation. HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment. “The oncological results for HIFU are broadly [...]

2017-12-13T13:37:23-08:00April 26th, 2016|

New Study Reveals Prostate Cancer Metastasis Risk Higher in Some AS Patients

Metastases develop in a small proportion of patients placed on active surveillance (AS) for prostate cancer (PCa), but the risk is significantly higher in some men than others, such as those with Gleason 7 tumors, a new study found. In a study of 980 men placed on AS—769 with low-risk and 211 with intermediate-risk PCa—a team led by Laurence Klotz, MD, of Sunnybrook Health Sciences Centre in Toronto found that 30 men (3%) progressed to metastatic disease at a median of 6.3 year after diagnosis, according to study findings published in The Journal of Urology (2016;195:1409-1414). Metastases developed in 13 (10%) of 133 patients with Gleason 7 disease. Metastases occurred in 16 low-risk and 14 intermediate-risk patients, and developed in bone in 18 patients and [...]

2017-12-13T13:37:23-08:00April 13th, 2016|